Open Nav

Fusion Genomics Corporation

Funding and partnership for proof of clinical utility studies.

  • Date:Thursday, October 18
  • Time:9:15 AM - 9:30 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Fusion Genomics is a precision medicine for infectious diseases company. Our mission is to put the power of next-generation sequencing within the reach of physicians enabling precise diagnosis and thus precise prescription. We solve the problem of non-diagnosis of diseases that is highly prevalent in hospital patients eg. around 70% of meningitis/encephalitis patients, 42% of upper respiratory patients, etc. Fusion has developed a platform that enables us to develop easy to use, cost-effective and powerful genomic tests for infectious diseases. Our main product is the ONETest PathoGenome which will diagnose and give clinically relevant genomic information about all known infectious disease in one panel. The platform enables results within 12 hours at 1/10th the cost of comparable whole metagenomic sequencing but with all the information.
  • Company Website:www.fusiongenomics.com
  • Company HQ City:Vancouver
  • Company HQ Country:Canada
  • Company HQ State:British Columbia
  • CEO/Top Company Official:Mohammad Qadir
  • Year Founded:2013
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development :ONETest PathoGenome - cost effective genomic test that diagnoses all known infectious diseases.
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:Fusion Genomics has completed the design of our ONETest PathoGenome tests that will diagnose all known infectious diseases. We are currently testing this in sub-sets syndromes - we have just completed a highly successful study of upper respiratory pathogens with RIVM, Netherlands and Sunnybrook Research Institute that was supported by big pharma. We are in discussions for studies of encephalitis/meningitis and sepsis with a variety of partners including McGill University and Stanford University. Fusion is raising a Series-A of $10 million to complete such studies, launch the Research Use Only version of the test and complete regulatory approvals for one or two syndromic indications. We are also looking for partners/clients who wish to test out our panel for clinical use.
  • Total Amount Raised to Date, In All Rounds:$1.2 million
Speakers
Mohammed Qadir
Fusion Genomics Corporoation
Back